Cara Therapeutics, Inc. financial data

Symbol
CARA on Nasdaq
Industry
Pharmaceutical Preparations
Location
400 Atlantic Street, Suite 500, Stamford, CT
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 467 % -29.7%
Quick Ratio 13.5 % +13.7%
Return On Equity -241 % -218%
Return On Assets -110 % -68.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.8M shares +1.42%
Common Stock, Shares, Outstanding 54.8M shares +1.42%
Entity Public Float 131M USD -68.6%
Common Stock, Value, Issued 54K USD 0%
Weighted Average Number of Shares Outstanding, Basic 54.7M shares +1.34%
Weighted Average Number of Shares Outstanding, Diluted 54.7M shares +1.34%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 11M USD -59.5%
Research and Development Expense 85.1M USD -19.2%
General and Administrative Expense 26.6M USD -4.35%
Operating Income (Loss) -108M USD +5.79%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -111M USD +0.52%
Earnings Per Share, Basic -2.05 USD/shares +0.49%
Earnings Per Share, Diluted -2.05 USD/shares +0.49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.2M USD -15.5%
Cash, Cash Equivalents, and Short-term Investments 56.6M USD -44.4%
Accounts Receivable, after Allowance for Credit Loss, Current 359K USD
Inventory, Net 1.64M USD -51.9%
Assets, Current 63.9M USD -48.8%
Property, Plant and Equipment, Net 3.49M USD +1033%
Operating Lease, Right-of-Use Asset 3.65M USD +360%
Assets 72.5M USD -46.1%
Accounts Payable, Current 6.76M USD -44.3%
Liabilities, Current 13.9M USD -45.4%
Operating Lease, Liability, Noncurrent 7.32M USD
Liabilities 60.9M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -121K USD +83.4%
Retained Earnings (Accumulated Deficit) -735M USD -17.8%
Stockholders' Equity Attributable to Parent 11.6M USD -89.4%
Liabilities and Equity 72.5M USD -46.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.5M USD +12%
Net Cash Provided by (Used in) Financing Activities -685K USD -222%
Net Cash Provided by (Used in) Investing Activities 26M USD +46.6%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 54.8M shares +1.42%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.7M USD -15.7%
Deferred Tax Assets, Valuation Allowance 193M USD +19.9%
Deferred Tax Assets, Gross 194M USD +20.3%
Operating Lease, Liability 7.49M USD +663%
Payments to Acquire Property, Plant, and Equipment 836K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -110M USD -0.11%
Lessee, Operating Lease, Liability, to be Paid 14.4M USD +1334%
Property, Plant and Equipment, Gross 4.99M USD +172%
Operating Lease, Liability, Current 168K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.33M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.3M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +85.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.88M USD +34315%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.36M USD
Deferred Tax Assets, Operating Loss Carryforwards 124M USD +9.45%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.4M USD
Operating Lease, Payments 1.99M USD +1.79%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 42K USD -27.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%